WCM Investment Management LLC Boosts Position in Insmed Incorporated (NASDAQ:INSM)

WCM Investment Management LLC lifted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 58.6% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 148,330 shares of the biopharmaceutical company's stock after buying an additional 54,806 shares during the quarter. WCM Investment Management LLC owned approximately 0.09% of Insmed worth $10,751,000 as of its most recent filing with the SEC.

A number of other large investors have also recently bought and sold shares of the business. Clearbridge Investments LLC acquired a new stake in Insmed in the first quarter worth approximately $25,242,000. Kennedy Capital Management LLC acquired a new position in shares of Insmed in the 1st quarter valued at $267,000. Russell Investments Group Ltd. raised its holdings in shares of Insmed by 15,915.2% during the first quarter. Russell Investments Group Ltd. now owns 22,101 shares of the biopharmaceutical company's stock valued at $600,000 after acquiring an additional 21,963 shares during the period. &PARTNERS purchased a new position in Insmed during the 2nd quarter worth approximately $300,000. Finally, TimesSquare Capital Management LLC purchased a new position in shares of Insmed during the third quarter valued at $35,322,000.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. UBS Group boosted their price objective on shares of Insmed from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday, August 9th. HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday, November 1st. TD Cowen upped their target price on shares of Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a research note on Friday, August 9th. Truist Financial reissued a "buy" rating and set a $105.00 price objective (up previously from $100.00) on shares of Insmed in a report on Friday, November 1st. Finally, Stifel Nicolaus boosted their price target on shares of Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a report on Friday, August 9th. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus price target of $83.07.

Insider Transactions at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the business's stock in a transaction dated Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total value of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares in the company, valued at $7,157,150. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of the firm's stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the transaction, the insider now directly owns 100,100 shares of the company's stock, valued at approximately $7,157,150. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Michael Alexander Smith sold 27,871 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $74.35, for a total value of $2,072,208.85. Following the completion of the transaction, the insider now directly owns 67,856 shares in the company, valued at approximately $5,045,093.60. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 78,882 shares of company stock worth $5,765,446 in the last three months. Corporate insiders own 4.60% of the company's stock.

Insmed Stock Down 2.3 %

Shares of NASDAQ INSM traded down $1.68 during mid-day trading on Tuesday, hitting $70.14. 1,665,500 shares of the stock traded hands, compared to its average volume of 2,252,233. The company has a market cap of $12.55 billion, a price-to-earnings ratio of -12.66 and a beta of 1.12. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53. The stock has a fifty day moving average price of $72.42 and a 200-day moving average price of $63.72.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. The business's revenue was up 18.1% compared to the same quarter last year. During the same period last year, the business posted ($1.10) earnings per share. Research analysts anticipate that Insmed Incorporated will post -5.42 EPS for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.